stockrow
Friday 6 November 2026
Export MREO’s income statement to Excel — free account
Mereo BioPharma Group plc - Sponsored ADR
MREO Healthcare Biotechnology
Mereo BioPharma Group plc - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $500,000.00, down 95.0% from fiscal 2023.
- EPS
- +52.3%
- Free cash flow
- +21.0%
Quarter to June 2026, against a year earlier
0.28
0.00
0.00%
Follow MREO
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 50 | — | 10 | — | 1 | — | (68.4%) | 14 | 14 | 7 | +138.4% | |
| Gross margin, % | — | — | — | — | — | 50.89 | 0.00 | 74.26 | — | 73.40 | 0.00 | +22.5 pt | ||||||
| EBT | — | — | (50) | (53) | (214) | 20 | (43) | (30) | (43) | (42) | (28) | (2.4%) | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 39.05 | 0.00 | (299.98) | 0.00 | (8,375.60) | 0.00 | (8,375.6) pt | ||||||
| Net income | — | — | (50) | (53) | (214) | 20 | (42) | (29) | (43) | (42) | (28) | (2.4%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.48 | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (3.00) | (2.49) | (3.08) | 0.14 | (0.37) | (0.20) | (0.29) | (0.26) | (0.17) | (29.4%) | ||||||
| Cash flow | — | — | (2.17) | (3.28) | (0.54) | (0.07) | (0.40) | (0.16) | (0.22) | (0.19) | (0.16) | (29.2%) | ||||||
| Capex | — | — | 0.00 | 0.00 | 0.03 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (6.1%) | ||||||
| Free cash flow | — | — | (2.17) | (3.28) | (0.50) | (0.07) | (0.40) | (0.16) | (0.23) | (0.20) | (0.16) | (29.1%) | ||||||
| Book value | — | — | 3.07 | 2.87 | (0.28) | 1.15 | 0.43 | 0.38 | 0.41 | 0.26 | 0.18 | (29.9%) | ||||||
| Shares, m | — | — | 14 | 18 | 68 | 106 | 121 | 132 | 148 | 159 | 160 | +41.2% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | — | 0.00 | — | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | 0.00 | — | 0.00 | — | 0.00 | 0.00 | 0.0 | ||||||
| P/B | — | — | — | — | — | 0.00 | — | 6.00 | — | 1.64 | 1.57 | 2.5 | ||||||
| EV/Sales | — | — | — | — | — | 0.00 | — | 0.00 | — | 0.00 | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | — | — | — | 2.11 | — | (11.45) | — | (0.98) | (0.77) | (3.4) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (31) | (59) | (36) | (7) | (49) | (21) | (33) | (31) | (25) | 0.0% | |||||
| Capex | — | — | 0 | 0 | 2 | (1) | 0 | 0 | (1) | 0 | 0 | +32.6% | ||||||
| Free cash flow | — | — | (31) | (59) | (34) | (8) | (49) | (22) | (34) | (31) | (26) | +0.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 24 | 1 | 27 | 119 | 51 | 54 | 61 | 41 | 28 | +7.6% | |||||
| Net debt | — | — | (8) | 5 | (9) | (110) | (68) | (53) | (70) | (41) | (30) | +26.1% | ||||||
| Shareholders’ equity | — | — | 44 | 51 | (19) | 121 | 51 | 51 | 61 | 41 | 29 | (0.9%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | 0.00 | (44.45) | (219.76) | 13.74 | (33.61) | (40.95) | (60.54) | (68.48) | (57.73) | (68.5) pt | |||||
| ROIC | — | — | (82.38) | (55.60) | 0.00 | (161.74) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +82.4 pt | ||||||
| ROE | — | — | 0.00 | (93.52) | (1,305.77) | 34.38 | (48.98) | (57.81) | (77.58) | (82.21) | (67.85) | (82.2) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | 37 | 50 | 38 | 49 | 36 | 33 | 36 | 39 | — | +0.8% | |||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.00 | 1.02 | 0.00 | 0.30 | 0.00 | 0.01 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2025
Mereo BioPharma Group plc - Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TIL Instil Bio, Inc. | $47.4M | — (loss-making) | — | — | n/m | +68.62% (above 0%: growing) | 0.00% | 0.00% | Compare |
| IMA ImageneBio, Inc. | $47.3M | — (loss-making) | — (loss-making) | −60.08% (below 0%: shrinking) | n/m | +23.76% (above 0%: growing) | 100.00% | 0.00% | Compare |
| HYFT MindWalk Holdings Corp. | $47.1M | — (loss-making) | — (loss-making) | +19.37% (above 0%: growing) | n/m | +9.79% (above 0%: growing) | 58.58% | (159.86%) | Compare |
| CNTB Connect Biopharma Holdings Limited Sponsored ADR | $46.1M | — (loss-making) | — (loss-making) | +296.56% (above 0%: growing) | n/m | −23.48% (below 0%: shrinking) | 100.00% | (635.98%) | Compare |
| MREO Mereo BioPharma Group plc - Sponsored ADR | $44.8M | — (loss-making) | — (loss-making) | — | n/m | +21.02% (above 0%: growing) | 0.00% | 0.00% | |
| IBIO iBio, Inc. | $44.4M | — (loss-making) | — (loss-making) | +100.00% (above 0%: growing) | n/m | −35.33% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CRBU Caribou Biosciences, Inc. | $44.2M | — (loss-making) | — (loss-making) | −26.89% (below 0%: shrinking) | n/m | +84.78% (above 0%: growing) | 100.00% | (1,720.10%) | Compare |
| BMEA Biomea Fusion, Inc. | $42.6M | — (loss-making) | — | — | n/m | +47.80% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ATHE Alterity Therapeutics Limited - Sponsored ADR | $42.4M | — (loss-making) | — | — | 0.00% | −84.83% (below 0%: shrinking) | 0.00% | — | Compare |
| Median of peers | $45.3M | — | — | +19.37% | — | +16.78% | 79.29% | 0.00% |
Pay and ownership Proxy statement filed 9 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 2.73m | (1.96m) | 55.56 |
| 2024 | 3.16m | 6.18m | 466.67 |
| 2023 | 2.22m | 5.45m | 308.00 |
Ownership
Directors and executive officers, together
6.50%
Entities affiliated with Rubric Capital Management LP
13.60%
Entities affiliated with EcoR1 Capital, LLC
9.30%
Entities affiliated with
8.20%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement